Generation and characterization of a novel fusion partner cell line for the production of human macrophage hybridoma.
Macrophages are important constituents of the immune system by exerting phagocytosis on invading pathogens as well as secreting various immunoregulatory factors. Generation of human macrophage hybridoma has not been possible so far due to the lack of an appropriate fusion partner cell line. In the present study, an 8'-azaguanine resistant cell line, termed HL-60R, was established by drug selection of the promyelocytic cell line HL-60. This novel cell line showed resistance to high concentrations of 8'-azaguanine and was sensitive to aminopterin. These characteristics make it suitable for serving as a potential fusion partner cell line in the development of macrophage hybridoma. Cell-surface analysis by FACS revealed that HL-60R cells per se do not express MHC-class II molecules or the macrophage marker, CD11b. PEG-mediated fusion of HL-60R was performed with PBMC-derived human macrophages. Fluorescence labelling of ex vivo isolated macrophages prior to fusion and subsequent FACS analysis showed that PEG-4000 is a more effective fusion agent than PEG-1500. The generation of this novel fusion partner cell line opens the possibility for development of human macrophage hybridoma or other cell lines from myelocytic origin. Such hybridoma clones will not only enable a more convenient study of these cell but will also provide an excellent host site for the proper production and expression of various recombinant proteins from myelocytic origin in vitro.
Park
J H
JH
Peptide Engineering Research Unit, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Taejon, Korea.
Cho
E W
EW
Lee
Y J
YJ
Hahm
K S
KS
Kim
K L
KL
D000630:Aminopterin / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001375:Azaguanine / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D005493:Folic Acid Antagonists / Q000494:pharmacology; D018922:HL-60 Cells / Q000187:drug effects; D006801:Humans; D006825:Hybridomas / Q000187:drug effects* / Q000502:physiology; D019271:Hypoxanthine / Q000494:pharmacology; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D008264:Macrophages / Q000187:drug effects*; D009154:Mutation; D013936:Thymidine / Q000494:pharmacology
D000964:Antimetabolites, Antineoplastic; D005493:Folic Acid Antagonists; D019271:Hypoxanthine; D007041:Hypoxanthine Phosphoribosyltransferase; D000630:Aminopterin; D001375:Azaguanine; D013936:Thymidine